Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
https://www.zacks.com/stock/news/2252898/bristol-myers-bmy-reports-positive-colorectal-cancer-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252898
Apr 09, 2024 - Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
https://www.zacks.com/stock/news/2251537/fate-therapeutics-fate-surges-86-4-ytd-on-pipeline-progress?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251537
Apr 05, 2024 - Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
0
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
https://www.zacks.com/stock/news/2249692/after-plunging-7-94-in-4-weeks-here-s-why-the-trend-might-reverse-for-galapagos-glpg?cid=CS-ZC-FT-tale_of_the_tape|rsi-2249692
Apr 03, 2024 - The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0